Phase 3 trial win sets up rare disease drug filing for CSL

VANUGUARD trial of garadacimab in HAE sets up a pursuit of Takeda's fast-growing Takhyzro.

CSL preps filings for once-monthly antibody for HAE

Australia's CSL has said its one-monthly treatment for hereditary angioedema has shown it is safe and effective in a phase 3 trial, and will be filed for approval in its current financial y

NICE backs BioCryst's Orladeyo for hereditary angioedema

BioCryst Pharma's Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE) in England, Wales and Northern Ireland.

CSL accuses ex-exec, now at Pharming, of stealing trade secr...

HAE patients get new option as NICE backs Takeda's Takhzyro

Patients in England and Wales with hereditary angioedema (HAE) should soon have a new treatment option after NICE recommended Takeda’s Takhzyro (lanadelumab) should be funded by the NHS in

FDA rejects Pharming's Ruconest HAE label expansion

The FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for patients with the serious rare disease hereditary angioedema (HAE).